When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ENTA - Enanta initiates early-stage NASH study with EDP-297
Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals (ENTA+2.0%) has dosed the first patient in its Phase 1 trial of EDP-297, potent and targeted follow-on farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
More news on: Enanta Pharmaceuticals, Inc., Healthcare stocks news,